journal
https://read.qxmd.com/read/38088033/clinical-outcomes-associated-with-anti-xa-monitored-enoxaparin-for-venous-thromboembolism-prophylaxis
#21
JOURNAL ARTICLE
John A Saunders, Sara R Vazquez, Joseph A Hill, Daniel M Witt
BACKGROUND: Most patients receiving Low-molecular-weight heparin therapy do not require routine coagulation monitoring, but due to uncertainty in certain populations, clinicians may feel compelled to perform anti-Xa monitoring. METHODS: This retrospective cohort study compared clinical outcomes in propensity-score matched adult inpatients from an academic health care system who did and did not receive anti-Xa monitoring of enoxaparin for venous thromboembolism prophylaxis...
December 13, 2023: Pharmacotherapy
https://read.qxmd.com/read/38050327/evaluation-of-the-safety-and-tolerability-of-intravenous-undiluted-levetiracetam-at-a-pediatric-institution
#22
JOURNAL ARTICLE
Lily Price, Lisa Garrity, Sarah Stiehl
STUDY OBJECTIVE: Recent studies suggest rapid administration of high-dose, undiluted levetiracetam is safe in adults; however, no information exists in pediatric patients. The purpose of this study was to evaluate the safety and tolerability of undiluted levetiracetam at a pediatric institution. DESIGN: Retrospective, single-center, cohort study. SETTING: Pediatric Academic Medical Center. PATIENTS: All patients who received high-dose >60 mg/kg (-10%) up to 4500 mg undiluted or diluted intravenous levetiracetam were included...
December 4, 2023: Pharmacotherapy
https://read.qxmd.com/read/38049205/acid-suppressive-drugs-a-systematic-review-and-network-meta-analysis-of-their-nocturnal-acid-inhibitory-effect
#23
JOURNAL ARTICLE
Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Minghui Sun
BACKGROUND AND AIMS: Acid-suppressive drugs (ASDs) are widely used in many gastric acid-associated diseases. Nocturnal acid breakthrough has been a common problem of many ASDs, such as proton-pump inhibitors (PPIs) and H2 -receptor antagonists (H2RAs). Potassium-competitive acid blockers (P-CABs) are expected to solve this continuing conundrum. This article examined major ASDs and compared them with placebo in terms of nocturnal acid-inhibitory effects, using a network meta-analysis of randomized controlled trials (RCTs)...
December 4, 2023: Pharmacotherapy
https://read.qxmd.com/read/37775945/kidney-function-as-a-key-driver-of-the-pharmacokinetic-response-to-high-dose-l-carnitine-in-septic-shock
#24
RANDOMIZED CONTROLLED TRIAL
Theodore S Jennaro, Michael A Puskarich, Thomas L Flott, Laura A McLellan, Alan E Jones, Manjunath P Pai, Kathleen A Stringer
STUDY OBJECTIVE: Levocarnitine (L-carnitine) has shown promise as a metabolic-therapeutic for septic shock, where mortality approaches 40%. However, high-dose (≥ 6 grams) intravenous supplementation results in a broad range of serum concentrations. We sought to describe the population pharmacokinetics (PK) of high-dose L-carnitine, test various estimates of kidney function, and assess the correlation of PK parameters with pre-treatment metabolites in describing drug response for patients with septic shock...
December 2023: Pharmacotherapy
https://read.qxmd.com/read/37772313/metabolomic-analysis-of-serum-samples-from-a-clinical-study-on-ipragliflozin-and-metformin-treatment-in-japanese-patients-with-type-2-diabetes-exploring-human-metabolites-associated-with-visceral-fat-reduction
#25
RANDOMIZED CONTROLLED TRIAL
Ayano Tsukagoshi-Yamaguchi, Masaya Koshizaka, Ryoichi Ishibashi, Ko Ishikawa, Takahiro Ishikawa, Mayumi Shoji, Shintaro Ide, Kana Ide, Yusuke Baba, Ryo Terayama, Akiko Hattori, Minoru Takemoto, Yasuo Ouchi, Yoshiro Maezawa, Koutaro Yokote
STUDY OBJECTIVE: The effects of the sodium-dependent glucose transporter-2 inhibitor ipragliflozin were compared with metformin in a previous study, which revealed that ipragliflozin reduced visceral fat content by 12%; however, the underlying mechanism was unclear. Therefore, this sub-analysis aimed to compare metabolomic changes associated with ipragliflozin and metformin that may contribute to their biological effects. DESIGN: A sub-analysis of a randomized controlled study...
December 2023: Pharmacotherapy
https://read.qxmd.com/read/37698371/cyp2d6-guided-opioid-therapy-for-adults-with-cancer-pain-a%C3%A2-randomized-implementation-clinical-trial
#26
RANDOMIZED CONTROLLED TRIAL
Scott A Mosley, Emily Cicali, Alex Del Cueto, Diane G Portman, Kristine A Donovan, Yan Gong, Taimour Langaee, Priya Gopalan, Jessica Schmit, Jason S Starr, Natalie Silver, Young D Chang, Sahana Rajasekhara, Joshua E Smith, Heloisa P Soares, Michael Clare-Salzler, Petr Starostik, Thomas J George, Howard L McLeod, Roger B Fillingim, J Kevin Hicks, Larisa H Cavallari
INTRODUCTION: The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer-related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6-guided opioid prescribing for patients with cancer and reported pilot outcome data. METHODS: Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation-effectiveness clinical trial and randomized to CYP2D6-genotype-guided opioid selection, with clinical recommendations, or usual care...
December 2023: Pharmacotherapy
https://read.qxmd.com/read/37681344/switching-from-intravenous-vancomycin-to-oral-antibiotics-reduces-adverse-events-in-a-retrospective-cohort-of-outpatients-with-orthopedic-infections
#27
JOURNAL ARTICLE
Chanah K Gallagher, Heather Cummins, Russell J Benefield, Laura K Certain
INTRODUCTION: Vancomycin is frequently used for prolonged courses in treating osteoarticular infections despite a high rate of adverse drug events (ADE). The objective of this study was to evaluate the safety and effectiveness of transitioning to oral therapy compared to continuing parenteral vancomycin in patients with orthopedic infections. METHODS: We conducted a single-center, retrospective cohort study of patients with orthopedic infections discharged on parenteral vancomycin with a planned duration of at least 4 weeks...
December 2023: Pharmacotherapy
https://read.qxmd.com/read/37539477/potential-drug-drug-interactions-among-u-s-adults-treated-with-nirmatrelvir-ritonavir-a-cross-sectional-study-of-the-national-covid-cohort-collaborative-n3c
#28
JOURNAL ARTICLE
Xuya Xiao, Hemalkumar B Mehta, Jill Curran, Brian T Garibaldi, G Caleb Alexander
STUDY OBJECTIVE: To estimate the prevalence of potential moderate to severe drug-drug interactions (DDIs) involving nirmatrelvir/ritonavir, identify interacting medications, and evaluate risk factors associated with potential DDIs. DESIGN: Cross-sectional study. DATA SOURCE: Electronic health records from the National COVID Cohort Collaborative Enclave, one of the largest COVID-19 data resources in the United States. PATIENTS: Outpatients aged ≥18 years and started nirmatrelvir/ritonavir between December 23, 2021 and March 31, 2022...
December 2023: Pharmacotherapy
https://read.qxmd.com/read/37519116/review-of-anticoagulation-considerations-in-extracorporeal-membrane-oxygenation-support
#29
REVIEW
Sydney D T Graboyes, Phillip S Owen, Rickey A Evans, Theodore J Berei, Katarzyna M Hryniewicz, Ian B Hollis
Since its first success in 1975, extracorporeal membrane oxygenation (ECMO) has been used with increasing frequency for pulmonary and cardiopulmonary bypass. Use in adults has increased exponentially since the early 2000s, but despite thousands of international cannulations using both veno-arterial (VA) and veno-venous (VV) ECMO, there are still significant hemocompatibility-related adverse events. Current management of anticoagulation has been based on the Extracorporeal Life Support Organization guidance published in 2014 with recent updates published in 2022...
December 2023: Pharmacotherapy
https://read.qxmd.com/read/38009283/cardiovascular-adverse-events-in-patients-with-hepatocellular-carcinoma-receiving-vascular-endothelial-growth-factor-inhibitors
#30
JOURNAL ARTICLE
Fangzheng Yuan, Carrie Lenneman, Ronald Krone, Grant R Williams, Darryl Outlaw, Michael Katsnelson, Stephen Lirette
BACKGROUND: Vascular endothelial growth factor inhibitors, including tyrosine kinase inhibitors (TKIs) and anti-angiogenics, are first-line therapies for advanced and metastatic hepatocellular carcinoma. Although TKIs have a greater potential for off-target adverse effects compared with bevacizumab, a direct comparison of the risk of cardiovascular adverse events between these two types of therapies has not been performed. OBJECTIVE: To compare the incidence of and characterize cardiovascular adverse events in patients with hepatocellular carcinoma receiving TKIs versus bevacizumab...
November 27, 2023: Pharmacotherapy
https://read.qxmd.com/read/37984818/pharmacokinetics-pharmacodynamics-analysis-and-establishment-of-optimal-dosing-regimens-using-unbound-cefmetazole-concentration-for-patients-infected-with-extended-spectrum-%C3%AE-lactamase-producing-enterobacterales-esbl-e
#31
JOURNAL ARTICLE
Takaya Namiki, Yuta Yokoyama, Hideki Hashi, Rentaro Oda, Aya Jibiki, Hitoshi Kawazoe, Kazuaki Matsumoto, Sayo Suzuki, Tomonori Nakamura
INTRODUCTION: Recently, cefmetazole (CMZ) has been used to treat Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E). However, a concentration measurement method for CMZ has yet to be established, and a pharmacokinetic/pharmacodynamic (PK/PD) analysis using unbound CMZ concentrations in patients not undergoing hemodialysis (non-HD) and undergoing hemodialysis (HD) has not been performed. Therefore, this study aimed to establish methods for measuring CMZ concentrations, conduct a PK/PD analysis using unbound CMZ concentrations for ESBL-E, and investigate optimal dosing regimens for non-HD and HD patients...
November 20, 2023: Pharmacotherapy
https://read.qxmd.com/read/37974531/urinary-biomarkers-as-indicators-of-acute-kidney-injury-in-critically-ill-children-exposed-to-vancomycin
#32
JOURNAL ARTICLE
Autumn M Spyhalsky, Se Jin Kim, Calvin J Meaney, Nicholas M Smith, Dhaval K Shah, Amanda B Hassinger, Nicholas M Fusco
INTRODUCTION: The standard of care for detecting acute kidney injury (AKI) is change in serum creatinine (SCr) and urine output, which are limited. This study aimed to compare urinary biomarkers neutrophil gelatinase-associated lipocalin (uNGAL) with kidney injury molecule-1 (uKIM-1) in critically ill children exposed to vancomycin who did and did not develop AKI as defined by changes in SCr. METHODS: This was a single-center, prospective, clinical, observational cohort study at a large tertiary care children's hospital in an urban setting...
November 16, 2023: Pharmacotherapy
https://read.qxmd.com/read/37943163/comparison-of-different-sustained-release-opioids-and-acute-respiratory-conditions-in-patients-with-cancer-and-chronic-kidney-disease
#33
JOURNAL ARTICLE
Satoru Mitsuboshi, Shungo Imai, Hayato Kizaki, Satoko Hori
STUDY OBJECTIVE: Few data are available on the association between the use of oxycodone in patients with chronic kidney disease (CKD) and acute respiratory conditions. The aim of this study was to investigate whether oxycodone is associated with an increased risk of acute respiratory conditions in patients with cancer and CKD compared with other opioids. DESIGN AND SETTING: The data were obtained from a claims database in Japan. Patients with cancer and CKD who had received sustained-release opioids, including oral oxycodone, oral morphine, or transdermal fentanyl, between April 2014 and May 2021 were selected...
November 9, 2023: Pharmacotherapy
https://read.qxmd.com/read/37926925/association-between-household-opioid-prescriptions-and-risk-for-overdose-among-family-members-not-prescribed-opioids
#34
JOURNAL ARTICLE
Alan T Arakkal, Linnea A Polgreen, Cole G Chapman, Jacob E Simmering, Joseph E Cavanaugh, Philip M Polgreen, Aaron C Miller
BACKGROUND: Prescription opioids have contributed to the rise in opioid-related overdoses and deaths. The presence of opioids within households may increase the risk of overdose among family members who were not prescribed an opioid themselves. Larger quantities of opioids may further increase risk. OBJECTIVES: To determine the risk of opioid overdose among individuals who were not prescribed an opioid but were exposed to opioids prescribed to other family members in the household, and evaluate the risk in relation to the total morphine milligram equivalents (MMEs) present in the household...
November 5, 2023: Pharmacotherapy
https://read.qxmd.com/read/37926860/development-and-validation-of-a-model-to-predict-acute-kidney-injury-following-high-dose-methotrexate-in-patients-with-lymphoma
#35
JOURNAL ARTICLE
Mikhaila L Rice, Erin F Barreto, Andrew D Rule, Catherine E Martin, Huong L Truong, Kristin C Mara, Kianoush B Kashani, Carrie A Thompson, Thomas E Witzig, Jason N Barreto
STUDY OBJECTIVE: To develop and validate a model for predicting acute kidney injury (AKI) after high-dose methotrexate (HDMTX) exposure. DESIGN: Retrospective analysis. SETTING: Multisite integrated health system throughout Minnesota and Wisconsin. PATIENTS: Adult patients with lymphoma who received HDMTX as a 4-h infusion. MEASUREMENTS AND MAIN RESULTS: LASSO methodology was used to identify factors available at the outset of therapy that predicted incident AKI within 7 days following HDMTX...
November 5, 2023: Pharmacotherapy
https://read.qxmd.com/read/37926857/impact-of-medication-intensification-on-30-day-hospital-readmissions-in-a-geriatric-trauma-population-a-multicenter-cohort-study
#36
JOURNAL ARTICLE
Emily Kanis, Patrick Gallegos, Kailey Christman, Daniel Vazquez, Chanda Mullen, Michaelia D Cucci
BACKGROUND: Fall-related injuries are a significant health issue that occur in 25% of older adults and account for a significant number of trauma-related hospitalizations. Although medication intensification may increase the risk of hospital readmissions in non-trauma patients, data in a geriatric trauma population are lacking. OBJECTIVE: The primary objective was to evaluate the effect of medication intensification on 30-day hospital readmissions in geriatric patients hospitalized for fall-related injuries...
November 5, 2023: Pharmacotherapy
https://read.qxmd.com/read/37840471/precision-medicine-in-the-icu-one-size-fits-one-patient
#37
EDITORIAL
Jeffrey F Barletta, Jason A Roberts
No abstract text is available yet for this article.
November 2023: Pharmacotherapy
https://read.qxmd.com/read/37772645/developing-precision-based-multidisciplinary-pharmacotherapy-management-plans-in-the-critically-ill
#38
JOURNAL ARTICLE
William E Dager
No abstract text is available yet for this article.
November 2023: Pharmacotherapy
https://read.qxmd.com/read/37604646/approaches-to-precision-based-anticoagulation-management-in-the-critically-ill
#39
JOURNAL ARTICLE
William E Dager, Toby C Trujillo, Brian W Gilbert
Anticoagulant therapy is commonly associated with a high incidence of avoidable adverse events, especially in the acute care setting. This has led to several initiatives by key national health care stakeholders, including specific attention to The Joint Commission's National Patient Safety Goals, to improve anticoagulation management. The subject of special populations has long been identified as challenging by clinicians with the use of anticoagulants. This is driven in part by numerous variables that can contribute to hard outcomes such as bleeding, thrombosis, length of stay, hospital re-admission, morbidity, and mortality...
November 2023: Pharmacotherapy
https://read.qxmd.com/read/37596844/antimicrobial-pharmacokinetics-and-dosing-in-critically-ill-adults-receiving-prolonged-intermittent-renal-replacement-therapy-a-systematic-review
#40
REVIEW
Arvind Grewal, Pierre Thabet, Samuel Dubinsky, Debanjali Purkayastha, Kristy Wong, Ryan Marko, Swapnil Hiremath, Brian Hutton, Salmaan Kanji
Prolonged intermittent renal replacement therapy (PIRRT) is gaining popularity as a renal replacement modality in intensive care units, but there is a relative lack of guidance regarding antimicrobial clearance and dosing when compared with other modalities. The objectives of this systematic review were to: (1) identify and describe the pharmacokinetics (PK) of relevant antimicrobials used in critically ill adults receiving PIRRT, (2) evaluate the quality of evidence supporting these data, and (3) propose dosing recommendations based on the synthesis of these data...
November 2023: Pharmacotherapy
journal
journal
20313
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.